Skip to main content
Premium Trial:

Request an Annual Quote

BioFocus DPI, GSK, Alnylam, Shanghai GenePharma

BioFocus DPI Obtains Global License to Cresset Software
BioFocus DPI has upgraded its software license with Cresset BioMolecular Discovery, gaining global access to the entire range of Cresset’s molecular field software for use in drug discovery.
The new license also extends BioFocus DPI’s coverage to include its parent company, Galapagos. BioFocus DPI and Galapagos will now be able to apply molecular field technology to projects including internal research, compound library design, or drug-discovery projects for clients.
BioFocus DPI and Cresset have been collaborating for two years on the design and synthesis of BioFocus DPI’s FieldFocus libraries for ion-channel drug discovery. 

GSK Purchases SRU BIND Reader System for UK Facility
SRU Biosystems announced this week that GlaxoSmithKline has purchased a BIND Reader system for its drug-discovery site in Harlow, UK.
SRU has developed the BIND product line for cell-based applications, small molecule/fragment screening, and antibody screening. The BIND system includes the BIND Reader, software tools, and 96-, 384-, or 1,536-well microplates with proprietary coatings for attaching cells or proteins.
The BIND Reader uses SRU Biosystems’ optical biosensor technology and can be integrated into a semi-automated or fully automated environment for kinetic or endpoint assays in an HTS mode.

Alnylam Licenses RNAi IP to China’s Shanghai GenePharma
Alnylam Pharmaceuticals this week said it has granted a non-exclusive, worldwide license to its Kreutzer-Limmer patent family to Chinese reagent shop Shanghai GenePharma for manufacturing and marketing RNAi research products and services.
The patents, according to Alnylam, cover fundamental aspects of the structure and uses of RNAi products, including their use to mediate RNAi in mammalian cells and of RNAi-related mechanisms.
"Providing this license to Shanghai GenePharma represents our first business transaction in China,” Jason Rhodes, vice president of business development at Alnylam, said in a statement.
Specific terms of the license were not disclosed.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.